Physician profile
Mark R Jones
NPI 1922452945
$47,988.80
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,970 · 2021: $6,549 · 2022: $4,073 · 2023: $13K · 2024: $8,100 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,332 · Travel and Lodging: $5,063 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,743 · Consulting Fee: $4,680 · Grant: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,162.37 |
| Food and Beverage | $7,332.25 |
| Travel and Lodging | $5,063.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,742.50 |
| Consulting Fee | $4,680.00 |
| Grant | $416.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $19,694.75 | 2021-2024 | Senza, Vyrsa V1 |
| Spinefrontier, INC. | $12,971.33 | 2024-2025 | Nanofuse, Sijfuse, Inspan |
| Medtronic, INC. | $6,018.48 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Mml US, INC. | $2,211.35 | 2021-2022 | |
| Medtronic USA, INC. | $1,969.85 | 2020 | |
| Stratus Medical, LLC | $1,500.91 | 2021 | |
| Boston Scientific Corporation | $976.34 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Spr Therapeutics, INC | $600.86 | 2022-2024 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.44 | 2021 | |
| Collegium Pharmaceutical, INC. | $259.95 | 2023-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $242.86 | 2025 | Senza |
| Vertos Medical, INC. | $172.97 | 2022-2024 | Mild Device Kit |
| Tersera Therapeutics LLC | $166.10 | 2023-2025 | Prialt |
| Lilly USA, LLC | $142.49 | 2021-2023 | Emgality, Reyvow |
| Abbott Laboratories | $103.67 | 2022-2025 | Eterna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $82.25 | 2023-2024 | Nalu Neurostimulation System |
| Hikma Pharmaceuticals USA | $76.34 | 2022-2024 | Kloxxado |
| Abbvie INC. | $72.28 | 2022-2024 | |
| Spinal Simplicity, LLC | $72.18 | 2025 | Ha Minuteman G3-R |
| Painteq LLC | $56.06 | 2022-2023 | Painteq |
| Relievant Medsystems, INC. | $50.71 | 2021 | |
| Bsn Medical INC | $48.46 | 2022 | |
| Curonix LLC | $45.29 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amgen INC. | $38.22 | 2023 | Evenity, Prolia |
| Scilex Pharmaceuticals INC. | $31.17 | 2022-2024 | |
| Biotronik Nro, INC. | $25.50 | 2025 | Prospera |
| Saluda Medical Americas, INC. | $25.15 | 2025 | Evoke |
| Avanos Medical | $22.16 | 2024 | Standard Rf Disposables |
| Si-Bone, INC. | $19.02 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.85 | 2022 | |
| Horizon Therapeutics Plc | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.